MOF-Based Strategies for mRNA Encapsulation and Delivery: A Technical Perspective

Study Background and Research Question

Messenger RNA (mRNA) technologies have rapidly advanced since the emergence of mRNA vaccines, underscoring the need for efficient, safe, and stable delivery systems. Traditional viral vectors, though effective, face significant barriers including immunogenicity, high production costs, restricted cargo capacity, and safety concerns. The search for scalable and tunable non-viral delivery vehicles has therefore become a central objective in gene therapy and nucleic acid therapeutics.

Metal-organic frameworks (MOFs) have been widely studied for applications such as catalysis and gas storage, but their use in biomedicine—especially for nucleic acid delivery—is relatively new. While prior work established MOFs as promising vehicles for small molecule drugs and short nucleic acids (e.g., siRNA, sgRNA), the encapsulation and delivery of much larger and more fragile mRNA molecules remained unaddressed. The reference study (Lawson et al., 2025) directly tackles this gap, formulating a strategy to encapsulate, stabilize, and deliver functional mRNA using MOF-based nanocarriers.

Key Innovation from the Reference Study

The central innovation reported is the encapsulation of mRNA within zeolitic imidazole framework-8 (ZIF-8) nanoparticles, with a polyethyleneimine (PEI) core forming a robust polymer complex. By integrating PEI, the researchers achieved several key advances:

• Stabilization of mRNA within the MOF matrix, preventing premature release or degradation in biological media
• Controlled, delayed release of the encapsulated mRNA, enabling sustained protein expression
• Successful delivery of mRNA and demonstration of protein expression both in vitro (multiple cell lines) and in vivo (mice)

Crucially, this is the first demonstration of mRNA encapsulation within a MOF enabling gene delivery, overcoming previous challenges related to mRNA loss and instability when exposed to physiological environments (Lawson et al., 2025).

Methods and Experimental Design Insights

The researchers systematically optimized the encapsulation process, leveraging the following strategy:

• Initial attempts at direct mRNA loading into ZIF-8 revealed rapid mRNA loss in biological media.
• To enhance retention, a PEI-mRNA complex was first formed, leveraging electrostatic interactions between the cationic polymer and the negatively charged mRNA.
• This PEI-mRNA core was then encapsulated within a ZIF-8 shell, resulting in a core-shell nanoparticle architecture.
• Extensive physicochemical characterizations (e.g., DLS, electron microscopy, zeta potential assays) were performed to confirm nanoparticle morphology, size, and stability.
• Functional assays included tracking mRNA integrity after encapsulation, quantifying protein expression via reporter gene (luciferase) assays, and comparing MOF-based delivery to commercial lipid nanoparticle systems.
• Storage studies assessed mRNA stability and activity following long-term room-temperature storage (up to 3 months in vitro, 1 month in vivo).

Protocol Parameters

• PEI:mRNA complexation: Prepare PEI:mRNA at an optimized N/P ratio (typically between 10:1 and 20:1 for maximal encapsulation and minimal cytotoxicity).
• ZIF-8 shell formation: Add zinc acetate and 2-methylimidazole to the PEI-mRNA solution under mild mixing at room temperature; allow for nanoparticle self-assembly (30-60 min).
• Stability assays: Incubate nanoparticles in physiological buffer (e.g., PBS with 10% FBS) at 37°C and monitor mRNA retention over 24-48 hours.
• Reporter expression assay: Transfect mammalian cells with MOF-encapsulated mRNA; measure luciferase activity 24-72 hours post-transfection.
• Storage conditions: Store dried or lyophilized nanoparticles at room temperature; periodically reconstitute and assay for protein expression.

Core Findings and Why They Matter

The study's findings address several longstanding challenges in mRNA therapeutic delivery:

• Efficient mRNA Delivery and Protein Expression: The PEI/ZIF-8 MOF system enabled robust luciferase expression in multiple mammalian cell lines and in mouse models, with efficacy on par with state-of-the-art lipid nanoparticle systems (Lawson et al., 2025).
• Enhanced Stability and Storage: Encapsulated mRNA retained biological activity after three months of room-temperature storage in vitro and for at least one month in vivo. This is a significant advance over current mRNA formulations, which typically require cold chain logistics.
• Reduced Innate Immune Activation: The MOF shell physically protects mRNA from nucleases and may also shield immunogenic motifs, supporting the goal of minimizing innate immune activation during delivery.
• Potential for Tunability and Scalability: The modular MOF synthesis allows for further functionalization or cargo adaptation, setting the stage for broader nucleic acid delivery applications.

Collectively, these advances demonstrate that MOF-based vehicles are not only compatible with large mRNA cargos, but also offer practical advantages for storage, distribution, and customizable delivery.

Comparison with Existing Internal Articles

Several recent internal reviews and commentary pieces have explored the landscape of advanced mRNA engineering and delivery, including the use of chemically modified, Cap1-capped, and fluorescently labeled mRNA for improved performance:

• The article "Translational Acceleration with EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP)" examines the impact of 5-moUTP modifications and Cap1 capping on translation efficiency and immune evasion. While the reference MOF study focuses on physical delivery barriers and storage, the internal article delves into molecular engineering of the mRNA itself for optimal performance in reporter gene and imaging assays.
• "EZ Cap Cy5 Firefly Luciferase mRNA: Dual-Mode Tracking & Expression" discusses dual-modality detection (bioluminescence and fluorescence) enabled by Cy5 labeling, which complements the delivery and stability advances described in the MOF encapsulation study.
• Together, these resources highlight the synergy between advanced carrier systems (such as MOFs) and molecularly engineered mRNA (e.g., 5-moUTP modification, fluorescent labeling), supporting workflows for mRNA delivery and transfection optimization, translation efficiency assays, and in vivo bioluminescence imaging.

Limitations and Transferability

Despite the promising results, several limitations should be noted:

• Translatability of MOF carriers: While ZIF-8/PEI systems demonstrated efficacy in cellular and mouse models, further studies are required to assess their safety, immunogenicity, and pharmacokinetics in larger animal models and human tissues.
• Cytotoxicity considerations: Polyethyleneimine, though effective for nucleic acid complexation, can be cytotoxic at high doses. Optimization of N/P ratios and surface modifications will be critical for clinical translation.
• Scalability and regulatory status: MOF-based nanoparticles, unlike lipid nanoparticles, are not yet widely adopted in clinical pipelines, and their manufacturing, quality control, and regulatory frameworks need further development.
• Generalizability to different mRNA cargos: The reference study focused on reporter mRNA; the adaptability to longer or highly structured therapeutic mRNAs remains to be validated.

Why this cross-domain matters, maturity, and limitations

The study bridges materials science (MOF engineering) and molecular biology (mRNA therapeutics), demonstrating that innovations in nanomaterials can address challenges in gene delivery, storage, and stability. This cross-domain approach is still in the early translational stage; while functional in animal models, MOF-based delivery systems have yet to reach clinical maturity. Their unique properties—such as room-temperature stability and modularity—could unlock new logistics and deployment paradigms for mRNA therapies, particularly in resource-limited settings.

Research Support Resources

For laboratories interested in benchmarking mRNA delivery or optimizing MOF-based and non-viral transfection workflows, chemically engineered mRNA controls are critical. The EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP) (SKU R1010) from APExBIO offers a dual-reporter mRNA with 5-methoxyuridine modifications, Cap1 capping, and Cy5 labeling. This reagent enables quantitative studies of translation efficiency, mRNA delivery, and intracellular trafficking—ideal for validating new carrier systems such as MOFs or for use in translation efficiency and in vivo imaging assays. For detailed guidance on experimental design, researchers may consult the referenced study and internal commentary articles above.